The DNAAF2 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical epithelial adenocarcinoma cell line, specifically targeting the DNAAF2 gene for disruption. This polyclonal population consists of a heterogeneous mixture of cells carrying various CRISPR-induced genetic alterations at the DNAAF2 locus, delivering a versatile loss-of-function model without single-cell cloning. It is designed for researchers studying the molecular requirements for axonemal dynein complex assembly and the regulation of motile cilia function in a human epithelial background.
HeLa cells, originally established from a cervical adenocarcinoma, are a cornerstone of biomedical research as a human epithelial cancer cell line. Their adherent growth, rapid proliferation, and extensive characterization make them ideal for gene knockout experiments and high-content screening. Although HeLa cells are not a classical model of multiciliated epithelium, they possess the molecular machinery for ciliogenesis and can be induced to form cilia under serum-starvation or other differentiation conditions, permitting the analysis of cilia-related gene function in an accessible in vitro setting.
DNAAF2 encodes a cytoplasmic assembly factor indispensable for the preassembly of axonemal dynein complexes, which power ciliary and flagellar motility. Transcriptionally governed by master ciliogenic regulators FOXJ1, RFX2, and RFX3, its expression aligns with the ciliogenesis program. At the protein level, DNAAF2 cooperates with assembly cofactors DNAAF1, LRRC6, and ZMYND10 to chaperone and integrate dynein heavy chains into inner and outer dynein arms. It directly interacts with dynein intermediate chains DNAI1 and DNAI2, stabilizing the macromolecular dynein architecture. DNAAF2 disruption consequently halts dynein arm formation, abrogating ciliary beat generation and phenocopying primary ciliary dyskinesia defects.
In the HeLa epithelial context, DNAAF2 knockout disrupts the cytoplasmic dynein assembly pathway, offering a simplified system to dissect its molecular role separate from the full multiciliated epithelium. When combined with ciliogenesis induction, this polyclonal population enables direct correlation between DNAAF2 loss and ciliary immotility, measured by high-speed video microscopy and immunofluorescence for axonemal markers. This model is especially relevant for primary ciliary dyskinesia research, as it recapitulates the dynein arm deficiency observed in patient respiratory and reproductive tissues, facilitating mechanistic studies and therapeutic screening in a controlled genetic environment.
Researchers can employ this polyclonal DNAAF2 knockout HeLa population for a range of assays, including RT-qPCR profiling of ciliogenesis genes, Western blot analysis of dynein components, and air-liquid interface culture to evaluate mucociliary clearance in differentiated epithelial layers. The cells support advanced disease modeling for primary ciliary dyskinesia, respiratory infection susceptibility, and infertility studies, providing a platform for functional rescue experiments with wild-type or mutant DNAAF2. Their polyclonal nature also preserves genetic diversity, reducing clone-specific artifacts and offering robust performance in pooled screening applications. For further technical information, pricing, or ordering assistance, please contact Ascent Research.
